미국의 피부과 치료제 시장 규모, 점유율, 동향 분석 : 치료법별, 종류별, 투여 경로별, 약물 종류별, 유통 채널별, 지역별, 부문별 예측(2025-2030년)

U.S. Dermatological Drugs Market Growth & Trends:

The U.S. dermatological drugs market size is anticipated to reach USD 14.48 billion by 2030, expanding at a CAGR of 9.7% from 2025 to 2030, according to a new report by Grand View Research, Inc. The growth of the market is driven by the availability of novel treatments designed for chronic skin diseases and the increasing prevalence of skin problems such as acne, psoriasis, and others. Increasing awareness regarding the significance of skin health in overall well-being also contributes to the growth.

Moreover, significant investments in research and development lead to new medications, and the availability of over-the-counter products makes treatments more accessible, contributing to overall growth. In recent years, multiple pharmaceutical and consumer healthcare companies have received U.S. FDA approvals for innovation-based products developed to treat severe skin conditions and enhance patient outcomes.

The emergence of new drug delivery systems and key market participants turning to collaboration-based research efforts in dermatology have also played vital roles in the market's growth. The large number of individuals seeking affordable treatments, the availability of over-the-counter products across retail pharmacies, and retailer service expansions with novel offerings such as fast delivery and online distribution are projected to add lucrative growth opportunities for this market over the forecast period.

U.S. Dermatological Drugs Market Report Highlights:

• Psoriasis dominated the therapy segment with more than 35.0% share in 2024, owing to many individuals seeking effective treatment for psoriasis and the focus of market participants on the delivery of novel therapies
• Dermatological drugs for acne are expected to grow at a significant CAGR in the U.S. over the forecast period
• The prescription-based dermatological drugs held the largest market share, 77.5%, in 2024. The over-the-counter segment is anticipated to witness significant growth over the forecast period
• Topical administration dominated the U.S. dermatological drugs market, with a revenue share of 60.0% in 2024, owing to patients' treatment experiences, patient-friendly delivery systems, and ease of use. The parenteral administration segment is expected to witness the fastest CAGR of 10.7% over the forecast period
• Increasing investments in research and development, approvals received for numerous novel therapies and products, and convenience offered by retail pharmacies are contributing to the growth of the U.S. dermatological drugs market.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Therapy
  • 1.2.2. Type
  • 1.2.3. Route of Administration
  • 1.2.4. Drug Class
  • 1.2.5. Distribution Channel
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. U.S. Dermatological Drugs Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis

Chapter 4. U.S. Dermatological Drugs Market: Therapy Estimates & Trend Analysis

• 4.1. Therapy Market Share, 2024 & 2030
• 4.2. Therapy Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Therapy, 2018 to 2030 (USD Million)
• 4.4. Acne
  • 4.4.1. Acne Market, 2018 - 2030 (USD Million)
• 4.5. Psoriasis
  • 4.5.1. Psoriasis Market, 2018 - 2030 (USD Million)
• 4.6. Rosacea
  • 4.6.1. Rosacea Market, 2018 - 2030 (USD Million)
• 4.7. Alopecia
  • 4.7.1. Alopecia Market, 2018 - 2030 (USD Million)
• 4.8. Others
  • 4.8.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. U.S. Dermatological Drugs Market: Type Estimates & Trend Analysis

• 5.1. Type Market Share, 2024 & 2030
• 5.2. Type Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Type, 2018 to 2030 (USD Million)
• 5.4. Prescription
  • 5.4.1. Prescription Market, 2018 - 2030 (USD Million)
• 5.5. Over-the-Counter (OTC)
  • 5.5.1. Over-the-Counter (OTC) Market, 2018 - 2030 (USD Million)

Chapter 6. U.S. Dermatological Drugs Market: Route of Administration Estimates & Trend Analysis

• 6.1. Route of Administration Market Share, 2024 & 2030
• 6.2. Route of Administration Segment Dashboard
• 6.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
• 6.4. Topical Administration
  • 6.4.1. Topical Administration Market, 2018 - 2030 (USD Million)
• 6.5. Oral Administration
  • 6.5.1. Oral Administration Market, 2018 - 2030 (USD Million)
• 6.6. Parenteral Administration
  • 6.6.1. Parenteral Administration Market, 2018 - 2030 (USD Million)

Chapter 7. U.S. Dermatological Drugs Market: Drug Class Estimates & Trend Analysis

• 7.1. Drug Class Channel Market Share, 2024 & 2030
• 7.2. Drug Class Channel Segment Dashboard
• 7.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)
• 7.4. Corticosteroids
  • 7.4.1. Corticosteroids Market, 2018 - 2030 (USD Million)
• 7.5. Retinoids
  • 7.5.1. Retinoids Market, 2018 - 2030 (USD Million)
• 7.6. Antibiotics
  • 7.6.1. Antibiotics Market, 2018 - 2030 (USD Million)
• 7.7. Antifungals
  • 7.7.1. Antifungals Market, 2018 - 2030 (USD Million)
• 7.8. Calcineurin Inhibitors
  • 7.8.1. Calcineurin Inhibitors Market, 2018 - 2030 (USD Million)
• 7.9. Others
  • 7.9.1. Others Market, 2018 - 2030 (USD Million)

Chapter 8. U.S. Dermatological Drugs Market: Distribution Channel Estimates & Trend Analysis

• 8.1. Distribution Channel Market Share, 2024 & 2030
• 8.2. Distribution Channel Segment Dashboard
• 8.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
• 8.4. Hospital Pharmacies
  • 8.4.1. Hospital Facilities Market, 2018 - 2030 (USD Million)
• 8.5. Retail Pharmacies
  • 8.5.1. Retail Facilities Market, 2018 - 2030 (USD Million)
• 8.6. Ohers
  • 8.6.1. Others Market, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Participant Overview
• 9.2. Company Market Position Analysis
• 9.3. Company Categorization
• 9.4. Strategy Mapping
• 9.5. Company Profiles/Listing
  • 9.5.1. AbbVie Inc.
    • 9.5.1.1. Overview
    • 9.5.1.2. Financial Performance
    • 9.5.1.3. Product Benchmarking
    • 9.5.1.4. Strategic Initiatives
  • 9.5.2. Pfizer Inc.
    • 9.5.2.1. Overview
    • 9.5.2.2. Financial Performance
    • 9.5.2.3. Product Benchmarking
    • 9.5.2.4. Strategic Initiatives
  • 9.5.3. GSK plc.
    • 9.5.3.1. Overview
    • 9.5.3.2. Financial Performance
    • 9.5.3.3. Product Benchmarking
    • 9.5.3.4. Strategic Initiatives
  • 9.5.4. LEO Pharma A/S
    • 9.5.4.1. Overview
    • 9.5.4.2. Financial Performance
    • 9.5.4.3. Product Benchmarking
    • 9.5.4.4. Strategic Initiatives
  • 9.5.5. Sun Pharmaceutical Industries Ltd.
    • 9.5.5.1. Overview
    • 9.5.5.2. Financial Performance
    • 9.5.5.3. Product Benchmarking
    • 9.5.5.4. Strategic Initiatives
  • 9.5.6. GALDERMA
    • 9.5.6.1. Overview
    • 9.5.6.2. Financial Performance
    • 9.5.6.3. Product Benchmarking
    • 9.5.6.4. Strategic Initiatives
  • 9.5.7. Amgen Inc.
    • 9.5.7.1. Overview
    • 9.5.7.2. Financial Performance
    • 9.5.7.3. Product Benchmarking
    • 9.5.7.4. Strategic Initiatives
  • 9.5.8. Johnson & Johnson Services Inc.
    • 9.5.8.1. Overview
    • 9.5.8.2. Financial Performance
    • 9.5.8.3. Product Benchmarking
    • 9.5.8.4. Strategic Initiatives
  • 9.5.9. Novartis AG
    • 9.5.9.1. Overview
    • 9.5.9.2. Financial Performance
    • 9.5.9.3. Product Benchmarking
    • 9.5.9.4. Strategic Initiatives
  • 9.5.10. Eli Lilly and Company
    • 9.5.10.1. Overview
    • 9.5.10.2. Financial Performance
    • 9.5.10.3. Product Benchmarking
    • 9.5.10.4. Strategic Initiatives
  • 9.5.11. Almirall, S.A
    • 9.5.11.1. Overview
    • 9.5.11.2. Financial Performance
    • 9.5.11.3. Product Benchmarking
    • 9.5.11.4. Strategic Initiatives
  • 9.5.12. Bausch Health Companies Inc.
    • 9.5.12.1. Overview
    • 9.5.12.2. Financial Performance
    • 9.5.12.3. Product Benchmarking
    • 9.5.12.4. Strategic Initiatives